Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.
Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.
Recruiting · NCT06692712 · Registry updated 2026-04-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls. | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, hereditary spastic paraplegia 50, nervous system disorder, palsy, paraplegia | Recruiting | Phase 3 | 2026-04-20 | NCT06692712 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Elpida Therapeutics SPC | 5 |
| Hospital Sant Joan de Deu | 15 |
| University of Texas Southwestern Medical Center | 295 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Sant Joan de Deu | Barcelona | Spain | 1 |
| University of Texas Southwestern Medical Center | Dallas | United States | 1 |